Ambit Inc. proudly announces that it has been named a winner in the Xcelerate RARE Open Science Data Challenge, hosted by Global Genes’ RARE-X. Our Data and Analytics team was recognized for its innovative computational approach in predicting disease diagnoses based on patient-reported data.
Ambit, a leading integrated biopharma solutions firm specializing in the rare and specialty disease markets, is pleased to announce a partnership with Datavant, the leader in helping organizations securely connect health data, to accelerate data-driven innovation for biopharma companies.
With an extensive background in the pharmaceutical industry and a passion for revolutionizing patient care, McNamara is poised to lead Ambit’s charge in elevating patient strategy to unprecedented heights within the rare and specialty disease sectors.
New branding emphasizes dedication and commitment to deliver best-in-class solutions for biopharma
With the goal of helping our clients solve their most complex challenges in biopharma, our approach has been to develop novel solutions by combining with advanced analytics, commercial, medical, and digital strategy, and omnichannel execution.
Former IPM.ai executive to drive data and analytics product strategy, development, and commercialization.
Our brand may be changing, but our focus remains the same. We are committed to developing novel solutions that enable our biopharma clients to adapt to the challenges and opportunities in the rare and specialty disease markets.
